ClinicalTrials.gg
RecruitingNCT06800196Updated Aug 5, 2026

A Study of KNT-0916 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

A Phase 1 interventional study of KNT-0916 in Solid Tumors With FGFR2 Alterations, Adult, sponsored by KinoTeck Therapeutics Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by KinoTeck Therapeutics Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
151
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a Phase1, open-label, dose escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of KNT-0916 in patients with unresectable or metastatic solid tumors harboring FGFR2 alterations who have failed prior systemic therapy. This study is divided into 2 parts, dose escalation part(part A), dose expansion part(partB).

Read the detailed description

This study is divided into 2 parts, part a isNdesigned to explore the maximum toxicity dose (MTD) of KNT-0916 with an accelerated titration plus traditional "3+3" design; part b is designed to explore the elementary anti-neoplastic activity of KNT-0916 with recommended dose in patients with confirmed FGFR2 alterations through central laboratory testing.

02

Conditions studied

  • Solid Tumors With FGFR2 Alterations, Adult
03

In context

Lead sponsor

This is the only study on the registry with KinoTeck Therapeutics Co., Ltd as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed unresectable or solid tumor
  • Documented FGFR2 gene fusion, mutation, or amplification per testing of blood and/or tumor
  • Patient must have per v1.1
  • Patient has performance status of 0-1
  • Patient must have disease that is to standard therapy, disease that has not adequately responded to standard therapy, disease for which standard or curative therapy does not exist, or the patient must be intolerant to or have declined standard therapy
  • An expected survival of ≥ 12 weeks.
  • Adequate organ function, as measured by laboratory values

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with any FGFR2 target therapy.
  • Central nervous system with associated symptom and signs.
  • , uncontrolled cardiovascular disease.
  • History of interstitial lung disease, or infectious pneumonitis need heavy antibiotics therapy 5. As judged by the investigator, unsuitable for attending the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
151 participants (estimated)

Study arms

  • Experimental
    Part A - dose escalation

    Dose escalation of KNT-0916 in patients with advanced solid tumors.

    Drug: KNT-0916

  • Experimental
    Part B - expansion

    Oral dose of KNT-0916 as determined during Part A Dose Escalation.

    Drug: KNT-0916

Interventions

  • DrugKNT-0916

    • KNT-0916 is an oral inhibitor of FGFR2.

06

What researchers measure

Primary outcomes

  1. Dose-limiting Toxicity (DLT)

    Time frame: 4 weeks

  2. Maximum tolerated dose (MTD) or Maximum administered dose (MAD)

    Time frame: 12 months

  3. Incidence, relatedness, seriousness and severity of adverse events (AEs) per the National Cancer Institute Common Terminology Criteria for AE (NCI CTCAE) Version 5.0.

    Time frame: 33 months

  4. Recommended phase 2 dose (RP2D)

    Time frame: 33 months

Secondary outcomes

  1. Objective response rate (ORR) assessed as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

    Time frame: 33 months

  2. Duration of response (DoR) assessed as per RECIST 1.1

    Time frame: 33 months

  3. Disease control rate (DCR) assessed as per RECIST 1.1

    Time frame: 33 months

  4. Progression-free survival (PFS) assessed as per RECIST 1.1

    Time frame: 33 months

  5. Overall survival (OS) assessed as per RECIST 1.1

    Time frame: 33 months

  6. Pharmacokinetic parameters including maximum plasma drug concentration (Cmax)

    Time frame: 33 months

  7. Pharmacokinetic parameters including area under the plasma concentration versus time curve (AUC)

    Time frame: 33 months

  8. Pharmacokinetic parameters including half-life (t1/2)

    Time frame: 33 months

  9. Pharmacokinetic parameters including time to maximum concentration (Tmax)

    Time frame: 33 months

  10. Pharmacokinetic parameters including Apparent clearance (CL/F)

    Time frame: 33 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Sep 2027, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2025
First posted
Jan 29, 2025
StartActual
Apr 10, 2025
Primary completionEst.
Sep 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06800196
Lead sponsor
KinoTeck Therapeutics Co., Ltd
Responsible party
Sponsor
First posted
Jan 29, 2025
Start date
Apr 10, 2025
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Aug 5, 2026

Study contacts

Lei Li
Contact
lilei@kino-biotech.com
0086 13711344347
Shaohua Chang
Contact
csh@kino-biotech.com
0086-13621109316
Ruihua Xu
principal investigator · Sun Yat-Sen University Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion